Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 178

1.

Corrigendum to "Advances in laparoscopic surgery for cervical cancer" [Crit. Rev. Oncol. Hematol. 143 (August) (2019) 76-80].

Bogani G, Leone Roberti Maggiore U, Rossetti D, Ditto A, Martinelli F, Chiappa V, Ferla S, Indini A, Sabatucci I, Lorusso D, Raspagliesi F.

Crit Rev Oncol Hematol. 2019 Nov 26;145:102833. doi: 10.1016/j.critrevonc.2019.102833. [Epub ahead of print] No abstract available.

PMID:
31783292
2.

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.

Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S.

Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607-5. doi: 10.1016/j.ygyno.2019.10.023. [Epub ahead of print]

PMID:
31699415
3.

Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.

Farolfi A, Lorusso D, Pignata S, De Giorgi U.

J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055. [Epub ahead of print] No abstract available.

PMID:
31697587
4.

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.

Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.

Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.

PMID:
31685558
5.

Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors.

De Giorgi U, Casadei C, Bergamini A, Attademo L, Cormio G, Lorusso D, Pignata S, Mangili G.

Cancers (Basel). 2019 Oct 17;11(10). pii: E1584. doi: 10.3390/cancers11101584. Review.

6.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

7.

Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.

Indini A, Di Guardo L, Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M.

J Gynecol Oncol. 2019 Nov;30(6):e94. doi: 10.3802/jgo.2019.30.e94.

8.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910962. [Epub ahead of print]

PMID:
31562799
9.

Advances in laparoscopic surgery for cervical cancer.

Bogani G, Maggiore ULR, Rossetti D, Ditto A, Martinelli F, Chiappa V, Ferla S, Indini A, Sabatucci I, Lorusso D, Raspagliesi F.

Crit Rev Oncol Hematol. 2019 Nov;143:76-80. doi: 10.1016/j.critrevonc.2019.07.021. Epub 2019 Aug 2. Review. Erratum in: Crit Rev Oncol Hematol. 2019 Nov 26;145:102833.

PMID:
31499276
10.

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.

Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators.

Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. doi: 10.1136/ijgc-2019-000370. Epub 2019 Aug 15.

PMID:
31420414
11.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

12.

RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.

Bogani G, Matteucci L, Tamberi S, Ditto A, Sabatucci I, Murgia F, Arcangeli V, Maltese G, Comerci G, Stefanetti M, Sonetto C, Calareso G, Marchiano A, Chiappa V, Lorusso D, Raspagliesi F.

Eur J Obstet Gynecol Reprod Biol. 2019 Jun;237:93-99. doi: 10.1016/j.ejogrb.2019.04.007. Epub 2019 Apr 8.

PMID:
31029972
13.

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S.

Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24.

PMID:
31029508
14.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators.

Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9.

PMID:
30979589
15.

Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.

Celio L, Saibene G, Lepori S, Festinese F, Niger M, Raspagliesi F, Lorusso D.

Tumori. 2019 Jun;105(3):253-258. doi: 10.1177/0300891619839301. Epub 2019 Apr 4.

PMID:
30945623
16.

Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.

Lorusso D, Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Raspagliesi F.

Tumori. 2019 Aug;105(4):282-287. doi: 10.1177/0300891619839308. Epub 2019 Mar 28. Review.

PMID:
30917765
17.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
18.

Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery.

Bogani G, Rossetti D, Ditto A, Martinelli F, Chiappa V, Leone C, Leone Roberti Maggiore U, Lorusso D, Raspagliesi F.

J Gynecol Oncol. 2019 Mar;30(2):e27. doi: 10.3802/jgo.2019.30.e27. Epub 2018 Nov 27.

19.

Treatment modalities for recurrent high-grade vaginal intraepithelial neoplasia.

Bogani G, Ditto A, Ferla S, Paolini B, Lombardo C, Lorusso D, Raspagliesi F.

J Gynecol Oncol. 2019 Mar;30(2):e20. doi: 10.3802/jgo.2019.30.e20. Epub 2018 Nov 8.

20.

Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.

Tripodi E, Cormio G, De Giorgi U, Valabrega G, Rubino D, Lepori S, Maltese G, Sabatucci I, Lorusso D.

Int J Gynecol Cancer. 2019 Jan;29(1):153-157. doi: 10.1136/ijgc-2018-000034. No abstract available.

PMID:
30640698

Supplemental Content

Loading ...
Support Center